The DOI matches its Crossref record.
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
Open accessAbstract
Because of rare but serious adverse events, pharmaceutical drugs and vaccines are sometimes withdrawn from the market, either by a government agency such as the Food and Drug Administration (FDA) in the United States or by the manufacturing pharmaceutical company. In other cases, a drug may be generally safe but increase the risk for serious adverse events for certain subpopulations such as pregnant women or people with heart problems. Due to limited sample size and selected study populations, rare adverse events are often impossible to detect during phase 3 trials conducted before the drug is approved for general use. It is then important to conduct post-approval drug safety surveillance, using, for example, health insurance claims data. In such surveillance, the goal should be to detect serious adverse events as early as possible without too many false alarms, and it is then natural to use a continuous or near-continuous sequential test procedure that reevaluates the data on a daily or weekly basis. In this article, we first show that Wald's classical sequential probability ratio test (SPRT) for continuous surveillance is very sensitive to the choice of relative risk required in the specification of the alternative hypothesis, making it difficult to use for drug and vaccine safety surveillance. We instead propose the use of a maximized sequential probability ratio test (MaxSPRT) based on a composite alternative hypothesis, which works well across a range of relative risks. We illustrate the use of this method on vaccine safety surveillance and compare it with the classical SPRT. A table of critical values for the MaxSPRT is provided, covering most parameter choices relevant for vaccine and drug safety surveillance. The critical values are based on exact numerical calculations. We also calculate the statistical power, the expected time until the null hypothesis is rejected, and the average length of surveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures
Klein, N. P., Fireman, B., Yih, W. K., Lewis, E., Kulldorff, M., Ray, P., Baxter, R., Hambidge, S., Nordin, J., Naleway, A., et al. (2010) · Pediatrics · doi:10.1542/peds.2010-0665 · Cited by 316
Self-citationTime-uniform, nonparametric, nonasymptotic confidence sequences
Howard, S. R., Ramdas, A., McAuliffe, J., & Sekhon, J. (2021) · The Annals of Statistics · doi:10.1214/20-aos1991 · Cited by 190
Li, R., Stewart, B., & Weintraub, E. (2016) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1052819 · Cited by 29
Statistical rules for safety monitoring in clinical trials
Martens, M. J., & Logan, B. R. (2024) · Clinical Trials · doi:10.1177/17407745231203391 · Cited by 10
Metadata
- Authors
- Kulldorff, M., Davis, R. L., Kolczak†, M., Lewis, E., Lieu, T., & Platt, R.
- Venue
- Sequential Analysis
- Publisher
- Informa UK Limited
- Published
- 2011-01-19
- Volume
- 30
- Issue
- 1
- Pages
- 58-78
- ISSN
- 0731-177X (ISSN-L)
- 0747-4946
- 1532-4176
- OpenAlex
- W2023071006
- Cited by
- 222
- References
- 0
- FWCI
- 28.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance. https://app.cochat.ai/papers/10.1080/07474946.2011.539924
- The paper
- Kulldorff, M., Davis, R. L., Kolczak†, M., Lewis, E., Lieu, T., & Platt, R. (2011). A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance. Sequential Analysis. https://doi.org/10.1080/07474946.2011.539924
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.